127 related articles for article (PubMed ID: 28972046)
1. Inhibiting PI3Kβ with AZD8186 Regulates Key Metabolic Pathways in PTEN-Null Tumors.
Lynch JT; Polanska UM; Delpuech O; Hancox U; Trinidad AG; Michopoulos F; Lenaghan C; McEwen R; Bradford J; Polanski R; Ellston R; Avivar-Valderas A; Pilling J; Staniszewska A; Cumberbatch M; Critchlow SE; Cruzalegui F; Barry ST
Clin Cancer Res; 2017 Dec; 23(24):7584-7595. PubMed ID: 28972046
[No Abstract] [Full Text] [Related]
2. Inhibition of PI3Kβ signaling with AZD8186 inhibits growth of PTEN-deficient breast and prostate tumors alone and in combination with docetaxel.
Hancox U; Cosulich S; Hanson L; Trigwell C; Lenaghan C; Ellston R; Dry H; Crafter C; Barlaam B; Fitzek M; Smith PD; Ogilvie D; D'Cruz C; Castriotta L; Wedge SR; Ward L; Powell S; Lawson M; Davies BR; Harrington EA; Foster E; Cumberbatch M; Green S; Barry ST
Mol Cancer Ther; 2015 Jan; 14(1):48-58. PubMed ID: 25398829
[TBL] [Abstract][Full Text] [Related]
3. Combined Inhibition of PI3Kβ and mTOR Inhibits Growth of PTEN-null Tumors.
Lynch JT; Polanska UM; Hancox U; Delpuech O; Maynard J; Trigwell C; Eberlein C; Lenaghan C; Polanski R; Avivar-Valderas A; Cumberbatch M; Klinowska T; Critchlow SE; Cruzalegui F; Barry ST
Mol Cancer Ther; 2018 Nov; 17(11):2309-2319. PubMed ID: 30097489
[TBL] [Abstract][Full Text] [Related]
4. Targeting PI3Kβ alone and in combination with chemotherapy or immunotherapy in tumors with PTEN loss.
Owusu-Brackett N; Zhao M; Akcakanat A; Evans KW; Yuca E; Dumbrava EI; Janku F; Meric-Bernstam F
Oncotarget; 2020 Mar; 11(11):969-981. PubMed ID: 32215185
[No Abstract] [Full Text] [Related]
5. High Efficacy of Combination Therapy Using PI3K/AKT Inhibitors with Androgen Deprivation in Prostate Cancer Preclinical Models.
Marques RB; Aghai A; de Ridder CMA; Stuurman D; Hoeben S; Boer A; Ellston RP; Barry ST; Davies BR; Trapman J; van Weerden WM
Eur Urol; 2015 Jun; 67(6):1177-1185. PubMed ID: 25220373
[TBL] [Abstract][Full Text] [Related]
6. The use of (18)F-fluorodeoxyglucose positron emission tomography ((18)F-FDG PET) as a pathway-specific biomarker with AZD8186, a PI3Kβ/δ inhibitor.
Maynard J; Emmas SA; Blé FX; Barjat H; Lawrie E; Hancox U; Oakes D; Polanska UM; Barry ST
EJNMMI Res; 2016 Dec; 6(1):62. PubMed ID: 27515445
[TBL] [Abstract][Full Text] [Related]
7. E-cadherin downregulation sensitizes PTEN-mutant tumors to PI3Kβ silencing.
Millán-Uclés Á; Zuluaga S; Marqués M; Vallejo-Díaz J; Sanz L; Cariaga-Martínez AE; Real FX; Carrera AC
Oncotarget; 2016 Dec; 7(51):84054-84071. PubMed ID: 27863432
[TBL] [Abstract][Full Text] [Related]
8. AKT-mTORC1 reactivation is the dominant resistance driver for PI3Kβ/AKT inhibitors in PTEN-null breast cancer and can be overcome by combining with Mcl-1 inhibitors.
Dunn S; Eberlein C; Yu J; Gris-Oliver A; Ong SH; Yelland U; Cureton N; Staniszewska A; McEwen R; Fox M; Pilling J; Hopcroft P; Coker EA; Jaaks P; Garnett MJ; Isherwood B; Serra V; Davies BR; Barry ST; Lynch JT; Yusa K
Oncogene; 2022 Nov; 41(46):5046-5060. PubMed ID: 36241868
[TBL] [Abstract][Full Text] [Related]
9. A Phase I Study Investigating AZD8186, a Potent and Selective Inhibitor of PI3Kβ/δ, in Patients with Advanced Solid Tumors.
Choudhury AD; Higano CS; de Bono JS; Cook N; Rathkopf DE; Wisinski KB; Martin-Liberal J; Linch M; Heath EI; Baird RD; García-Carbacho J; Quintela-Fandino M; Barry ST; de Bruin EC; Colebrook S; Hawkins G; Klinowska T; Maroj B; Moorthy G; Mortimer PG; Moschetta M; Nikolaou M; Sainsbury L; Shapiro GI; Siu LL; Hansen AR
Clin Cancer Res; 2022 Jun; 28(11):2257-2269. PubMed ID: 35247924
[TBL] [Abstract][Full Text] [Related]
10. Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3Kβ and PI3Kδ for the treatment of PTEN-deficient cancers.
Barlaam B; Cosulich S; Degorce S; Fitzek M; Green S; Hancox U; Lambert-van der Brempt C; Lohmann JJ; Maudet M; Morgentin R; Pasquet MJ; Péru A; Plé P; Saleh T; Vautier M; Walker M; Ward L; Warin N
J Med Chem; 2015 Jan; 58(2):943-62. PubMed ID: 25514658
[TBL] [Abstract][Full Text] [Related]
11. Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.
Schwartz S; Wongvipat J; Trigwell CB; Hancox U; Carver BS; Rodrik-Outmezguine V; Will M; Yellen P; de Stanchina E; Baselga J; Scher HI; Barry ST; Sawyers CL; Chandarlapaty S; Rosen N
Cancer Cell; 2015 Jan; 27(1):109-22. PubMed ID: 25544636
[TBL] [Abstract][Full Text] [Related]
12. AZD8186 in Combination With Paclitaxel in Patients With Advanced Gastric Cancer: Results From a Phase Ib/II Study (KCSG ST18-20).
Suh KJ; Ryu MH; Zang DY; Bae WK; Lee HS; Oh HJ; Kang M; Kim JW; Kim BJ; Mortimer PGS; Kim HJ; Lee KW
Oncologist; 2023 Sep; 28(9):e823-e834. PubMed ID: 37036671
[TBL] [Abstract][Full Text] [Related]
13. Concomitant Inhibition of PI3Kβ and BRAF or MEK in PTEN-Deficient/BRAF-Mutant Melanoma Treatment: Preclinical Assessment of SAR260301 Oral PI3Kβ-Selective Inhibitor.
Bonnevaux H; Lemaitre O; Vincent L; Levit MN; Windenberger F; Halley F; Delorme C; Lengauer C; Garcia-Echeverria C; Virone-Oddos A
Mol Cancer Ther; 2016 Jul; 15(7):1460-71. PubMed ID: 27196754
[TBL] [Abstract][Full Text] [Related]
14. The isomiR-140-3p-regulated mevalonic acid pathway as a potential target for prevention of triple negative breast cancer.
Bhardwaj A; Singh H; Trinidad CM; Albarracin CT; Hunt KK; Bedrosian I
Breast Cancer Res; 2018 Dec; 20(1):150. PubMed ID: 30537987
[TBL] [Abstract][Full Text] [Related]
15. mTOR inhibition amplifies the anti-lymphoma effect of PI3Kβ/δ blockage in diffuse large B-cell lymphoma.
Xu W; Berning P; Erdmann T; Grau M; Bettazová N; Zapukhlyak M; Frontzek F; Kosnopfel C; Lenz P; Grondine M; Willis B; Lynch JT; Klener P; Hailfinger S; Barry ST; Lenz G
Leukemia; 2023 Jan; 37(1):178-189. PubMed ID: 36352190
[TBL] [Abstract][Full Text] [Related]
16. Dual inhibition of MEK and PI3Kβ/δ-a potential therapeutic strategy in PTEN-wild-type docetaxel-resistant metastatic prostate cancer.
Ruiz de Porras V; Bernat-Peguera A; Alcon C; Laguia F; Fernández-Saorin M; Jiménez N; Senan-Salinas A; Solé-Blanch C; Feu A; Marín-Aguilera M; Pardo JC; Ochoa-de-Olza M; Montero J; Mellado B; Font A
Front Pharmacol; 2024; 15():1331648. PubMed ID: 38318136
[No Abstract] [Full Text] [Related]
17. INPP4B and PTEN Loss Leads to PI-3,4-P2 Accumulation and Inhibition of PI3K in TNBC.
Reed DE; Shokat KM
Mol Cancer Res; 2017 Jun; 15(6):765-775. PubMed ID: 28196852
[TBL] [Abstract][Full Text] [Related]
18. Combined targeting of G protein-coupled receptor and EGF receptor signaling overcomes resistance to PI3K pathway inhibitors in PTEN-null triple negative breast cancer.
Zecchin D; Moore C; Michailidis F; Horswell S; Rana S; Howell M; Downward J
EMBO Mol Med; 2020 Aug; 12(8):e11987. PubMed ID: 32672423
[TBL] [Abstract][Full Text] [Related]
19. Integrated molecular pathway analysis informs a synergistic combination therapy targeting PTEN/PI3K and EGFR pathways for basal-like breast cancer.
She QB; Gruvberger-Saal SK; Maurer M; Chen Y; Jumppanen M; Su T; Dendy M; Lau YK; Memeo L; Horlings HM; van de Vijver MJ; Isola J; Hibshoosh H; Rosen N; Parsons R; Saal LH
BMC Cancer; 2016 Aug; 16():587. PubMed ID: 27484095
[TBL] [Abstract][Full Text] [Related]
20. Untargeted stable isotope-resolved metabolomics to assess the effect of PI3Kβ inhibition on metabolic pathway activities in a PTEN null breast cancer cell line.
Lackner M; Neef SK; Winter S; Beer-Hammer S; Nürnberg B; Schwab M; Hofmann U; Haag M
Front Mol Biosci; 2022; 9():1004602. PubMed ID: 36310598
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
